Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone

Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer

Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
RR 2.97 [0.31, 28.09]
1 study · 205 participants
Low

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found